Biotech

All Articles

Regeneron's Opdualag rival reveals 57% feedback price

.Regeneron is back along with lasting follow-up for its own LAG-3 prevention and also PD-1 preventio...

AstraZeneca posts data on internal opponents to AbbVie, Pfizer ADCs

.AstraZeneca has shared an early look at the efficiency of its internal antibody-drug conjugate (ADC...

iTeos- GSK's TIGIT star presents significant remodeling

.After announcing a stage 3 launch based upon beneficial midstage results, iTeos as well as GSK are ...

More collaborative FDA can speed up rare disease R&ampD: file

.The FDA must be more open and also joint to release a surge in approvals of unusual illness medicat...

Zenas, MBX, Bicara head to Nasdaq in very hot time for biotech IPOs

.It is actually an abnormally active Friday for biotech IPOs, with Zenas BioPharma, MBX and also Bic...

Atea's COVID antiviral fails to halt hospital stays in phase 3

.Atea Pharmaceuticals' antiviral has actually stopped working one more COVID-19 trial, yet the biote...

Neurocrine's proposal to conserve mental illness possibility neglects

.Neurocrine Biosciences' schizophrenia course pivot has stopped working. The biotech was not able to...

Sanofi pays for $110M upfront for late-stage radioligand therapy

.Sanofi has actually brought in an overdue entry to the radioligand party, spending 100 million euro...

F 2G raises $100M for second effort to get brand-new antifungal to market

.After F2G's initial try to receive a brand-new training class of antifungal to market was actually ...

Moderna targets $1.1 B in R&ampD spending slices, drops 5 plans among productivity pressures

.Moderna has vowed to cut R&ampD spending by $1.1 billion by 2027. The decision to retract the finan...